Investment Thesis
Agenus exhibits critical financial deterioration with severe liquidity crisis, negative stockholders' equity of -$271.1M indicating technical insolvency, and massive cash burn of -$77.2M annually. Despite modest revenue growth of 10.4%, the company is operationally unprofitable with -$20.2M operating loss and cannot sustain operations without external capital infusion.
AGEN Strengths
- Revenue growth of 10.4% YoY shows top-line expansion in biologics sector
- Modest improvement in net loss from prior year (-101.0K vs larger prior loss)
- Recent insider activity with 8 Form 4 filings suggests management engagement
AGEN Risks
- Negative stockholders' equity of -$271.1M indicates technical insolvency and potential bankruptcy risk
- Severe liquidity crisis with current ratio of 0.41x and only $3.0M cash against $44.7M long-term debt
- Massive negative free cash flow of -$77.2M annually with -67.6% FCF margin unsustainable without funding
- Operating losses of -$20.2M despite revenue generation indicate fundamental business model problems
- Negative interest coverage of -0.6x shows inability to service debt from operations
Key Metrics to Watch
- Cash and equivalents trend - critical for survival without dilutive capital raises
- Operating cash flow trajectory - must show material improvement toward positive territory
- Revenue growth sustainability - verify 10.4% growth continues amid cash constraints
- Debt refinancing activities - watch for distressed negotiations affecting capital structure
AGEN Financial Metrics
AGEN Profitability Ratios
AGEN Balance Sheet & Liquidity
AGEN 5-Year Financial Trend
5-Year Trend Summary: AGENUS INC's revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-13.75 indicates the company is currently unprofitable.
AGEN Growth Metrics (YoY)
AGEN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $25.1M | $7.5M | $0.37 |
| Q2 2025 | $23.5M | -$26.4M | $-1.00 |
| Q1 2025 | $24.1M | -$26.4M | $-1.03 |
| Q3 2024 | $24.3M | -$54.8M | $-3.08 |
| Q2 2024 | $23.5M | -$54.8M | $-2.52 |
| Q1 2024 | $22.9M | -$63.5M | $-3.04 |
| Q3 2023 | $22.8M | -$49.2M | $-0.16 |
| Q2 2023 | $20.9M | -$49.2M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AGEN Capital Allocation
AGEN SEC Filings
Access official SEC EDGAR filings for AGENUS INC (CIK: 0001098972)